ticlopidine has been researched along with Thrombocytopenia in 68 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Platelet adenosine diphosphate (ADP) receptors may play a role in potentiating platelet activation induced by IgG from patients with immune heparin-induced thrombocytopenia (HIT), as shown by previous studies using the ADP receptor antagonists AR-C66096 and ticlopidine." | 7.73 | Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. ( Greinacher, A; Raschke, R; Rosenblood, GS; Schmidt, CO; Selleng, K; Selleng, S; Warkentin, TE, 2005) |
| "We report our experience with a case of isolated profound thrombocytopenia after clopidogrel (thienopyridine) administration." | 7.72 | [Clopidogrel and thrombopenia. A case report]. ( Beygui, F; Elalamy, I; Helft, G; Khellaf, C; Laudy, C; Le Feuvre, C; Metzger, JP; Monnet de Lorbeau, B; Ounissi, F; Tran, D, 2003) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 7.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 7.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine." | 7.70 | Ticlopidine-induced thrombocytopenia. ( de Vries, CJ; Koornstra, JJ; Loualidi, A, 1999) |
| "Healthcare professionals must be aware of the possibility of severe neutropenia and death caused by ticlopidine, even when the manufacturers' monitoring guidelines are followed." | 7.69 | Fatal neutropenia and thrombocytopenia associated with ticlopidine. ( Carlson, JA; Maesner, JE, 1994) |
| "Ticlopidine is a new drug for the inhibition of the aggregation of platelets, which is used in arteriosclerosis." | 7.67 | [Thrombocytopenia due to antibodies induced by ticlopidine]. ( Claas, FH; de Fraiture, WH; Meyboom, RH, 1984) |
| "A patient with chronic lymphocytic leukemia and thrombocytopenia who underwent percutaneous coronary intervention (PCI) and stenting is presented." | 5.33 | Successful percutaneous coronary intervention using bivalirudin in a patient with chronic lymphocytic leukemia and thrombocytopenia. ( Krolick, MA, 2006) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 5.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| " Because of better side-effect profile and simpler dosing regime, clopidogrel has largely replaced ticlopidine." | 5.31 | Isolated profound thrombocytopenia associated with clopidogrel. ( Elmi, F; Peacock, T; Schiavone, J, 2000) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| " A 5-day course of ticlopidine HCl immediately before surgery results in a significant reduction in the thrombopenia usually observed and attributed to platelet aggregation and adhesion to the apparatus." | 5.05 | [Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)]. ( Curtet, JM; Guilmet, D; Renner, C, 1980) |
| " We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction." | 4.91 | Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. ( Bainey, KR; Ferguson, C; Sharma, A, 2015) |
| " Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding." | 3.79 | The safety of thoracentesis in patients with uncorrected bleeding risk. ( Araujo, KL; Argento, AC; Murphy, TE; Pisani, MA; Puchalski, JT, 2013) |
| " A 35-year-old lady with ES taking aspirin with clopidogrel for thrombo-prophylaxis presented with massive epistaxis." | 3.77 | Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum. ( Liu, A; Pusalkar, P; Saman, H, 2011) |
| "Platelet adenosine diphosphate (ADP) receptors may play a role in potentiating platelet activation induced by IgG from patients with immune heparin-induced thrombocytopenia (HIT), as shown by previous studies using the ADP receptor antagonists AR-C66096 and ticlopidine." | 3.73 | Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. ( Greinacher, A; Raschke, R; Rosenblood, GS; Schmidt, CO; Selleng, K; Selleng, S; Warkentin, TE, 2005) |
| "We report our experience with a case of isolated profound thrombocytopenia after clopidogrel (thienopyridine) administration." | 3.72 | [Clopidogrel and thrombopenia. A case report]. ( Beygui, F; Elalamy, I; Helft, G; Khellaf, C; Laudy, C; Le Feuvre, C; Metzger, JP; Monnet de Lorbeau, B; Ounissi, F; Tran, D, 2003) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 3.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine." | 3.70 | Ticlopidine-induced thrombocytopenia. ( de Vries, CJ; Koornstra, JJ; Loualidi, A, 1999) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 3.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "Healthcare professionals must be aware of the possibility of severe neutropenia and death caused by ticlopidine, even when the manufacturers' monitoring guidelines are followed." | 3.69 | Fatal neutropenia and thrombocytopenia associated with ticlopidine. ( Carlson, JA; Maesner, JE, 1994) |
| "Ticlopidine is a new drug for the inhibition of the aggregation of platelets, which is used in arteriosclerosis." | 3.67 | [Thrombocytopenia due to antibodies induced by ticlopidine]. ( Claas, FH; de Fraiture, WH; Meyboom, RH, 1984) |
| " Oral administration of ticlopidine inhibited the transient thrombocytopenia caused by ADP." | 3.66 | Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP. ( Butler, KD; White, AM, 1980) |
| "Major bleeding was registered in one (less than 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| "The mean aortic regurgitation grade was unchanged." | 2.72 | Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. ( Buellesfeld, L; Felderhoff, T; Gerckens, U; Grube, E; Iversen, S; Laborde, JC; Menichelli, M; Mueller, R; Sauren, B; Schmidt, T; Stone, GW; Zickmann, B, 2006) |
| " Additionally, it provides an overview of tirofiban's pharmacology and summary of the clinical efficacy and safety data of two dosing regimens." | 2.46 | Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010) |
| "Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon." | 2.41 | Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. ( Fragopanagou, E; Galani, A; Giannakoulas, N; Kouraklis-Symeonidis, A; Matsouka, P; Seimeni, U; Symeonidis, A; Tiniakou, M; Zoumbos, N, 2002) |
| "Drug-induced thrombocytopenia is a phenomenon that causes significant morbidity and mortality among patients." | 2.41 | Drug-induced thrombocytopenia in the coronary care unit. ( Gandhi, PJ; Patnode, NM, 2000) |
| "Ticlopidine is an antiplatelet agent that is used to reduce the occurrence of atherothrombotic arterial events." | 2.40 | Adverse haematological effects of ticlopidine. Prevention, recognition and management. ( Biller, J; Gent, M; Love, BB, 1998) |
| "Methods Antibody-mediated TRALI was experimentally induced in mice by lipopolysaccharide priming followed by the administration of an anti-MHC I mAb." | 1.43 | Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. ( de la Salle, H; El Mdawar, MB; Gachet, C; Hechler, B; Heim, V; Magnenat, S; Maître, B, 2016) |
| "In patients, thrombocytopenia is correlated with an adverse outcome of pneumonia." | 1.42 | Thrombocytopenia impairs host defense during murine Streptococcus pneumoniae pneumonia. ( Brands, X; de Stoppelaar, SF; Roelofs, JJ; Schouten, M; Schultz, MJ; van den Boogaard, FE; van der Poll, T; van't Veer, C, 2015) |
| "Pocket hematoma is a troublesome complication associated with the implantation of cardiac implantable electronic devices (CIEDs)." | 1.39 | Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation. ( Chang, JP; Chen, HC; Chen, MC; Chen, YL; Guo, BF; Lin, YS; Pan, KL; Tsai, TH, 2013) |
| "Remarkably, hyperalgesia evoked by Bjv or carrageenan was completely blocked in animals treated with ARPI or busulfan, or pre-treated with aspirin or clopidogrel." | 1.37 | Involvement of circulating platelets on the hyperalgesic response evoked by carrageenan and Bothrops jararaca snake venom. ( Cirillo, MC; Giorgi, R; Gonçalves, LR; Nogueira, TO; Sano-Martins, IS; Santoro, ML; Senise, LV; Yamashita, KM, 2011) |
| "Acute coronary syndrome is uncommon in patients who have thrombocytopenia; however, it occurs in up to 39% of patients who have both thrombocytopenia and cancer." | 1.36 | Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010) |
| "A patient with chronic lymphocytic leukemia and thrombocytopenia who underwent percutaneous coronary intervention (PCI) and stenting is presented." | 1.33 | Successful percutaneous coronary intervention using bivalirudin in a patient with chronic lymphocytic leukemia and thrombocytopenia. ( Krolick, MA, 2006) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | 1.32 | Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| " The present study evaluated the pharmacokinetic and pharmacological interactions between KGK and ticlopidine hydrochloride." | 1.32 | Pharmacokinetic and pharmacological interactions between ticlopidine hydrochloride and Kangen-Karyu - Chinese traditional herbal medicine. ( Deguchi, Y; Kano, Y; Makino, T; Okamoto, T; Okukubo, Y; Wakushima, H, 2003) |
| " Because of better side-effect profile and simpler dosing regime, clopidogrel has largely replaced ticlopidine." | 1.31 | Isolated profound thrombocytopenia associated with clopidogrel. ( Elmi, F; Peacock, T; Schiavone, J, 2000) |
| "0 to 50 microg/mL and ex vivo in a patient dosed at 250 mg/day." | 1.30 | Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. ( Fareed, J; Haas, S; Jeske, WP; Walenga, JM, 1999) |
| "Kasabach-Merritt syndrome is an infrequent combination of a giant hemangioma and severe thrombocytopenia." | 1.30 | -Neonatal Kasabach-Merritt syndrome healed by complete surgical excision of the angioma-. ( Dupont, D; Golkar, A; Valla, JS; Velin, P, 1998) |
| "Anemia and disseminated intravascular coagulation may develop." | 1.28 | [Kasabach-Merritt syndrome in children]. ( Andry, P; Bodemer, C; Brunelle, F; de Prost, Y; Hubert, P; Nihoul-Fékété, C; Sebag, G; Teillac-Hamel, D, 1992) |
| " From a dose-response showing that the administration of increasing doses of tissue thromboplastin resulted in a subsequent progressive increase of thrombus weight, two concentrations of tissue thromboplastin were chosen: a high dose (550 microL/kg, IV) where thrombus formation was optimal and a concentration (7 microL/kg, IV) where tissue thromboplastin-hypercoagulability was intermediate." | 1.28 | Importance of platelets in experimental venous thrombosis in the rat. ( Bernat, A; Herbert, JM; Maffrand, JP, 1992) |
| "In 8 patients with liver cirrhosis who underwent hepatectomy, one patient with a prolonged T2 (260 secs) and a normal skin BT bled postoperatively, however, 3 patients with a prolonged skin BT (greater than 15 min) and a normal T2 had no hemorrhagic complications." | 1.27 | Clinical application of a new in vitro bleeding time device on surgical patients. ( Itoh, T; Kambayashi, J; Mori, T; Sakon, M; Tsujinaka, T; Uemura, Y, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (14.71) | 18.7374 |
| 1990's | 15 (22.06) | 18.2507 |
| 2000's | 24 (35.29) | 29.6817 |
| 2010's | 19 (27.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valgimigli, M | 2 |
| Costa, F | 1 |
| Chen, HC | 1 |
| Chen, YL | 1 |
| Guo, BF | 1 |
| Tsai, TH | 1 |
| Chang, JP | 1 |
| Pan, KL | 1 |
| Lin, YS | 1 |
| Chen, MC | 1 |
| Puchalski, JT | 1 |
| Argento, AC | 1 |
| Murphy, TE | 1 |
| Araujo, KL | 1 |
| Pisani, MA | 1 |
| Jy, W | 1 |
| Johansen, ME | 1 |
| Bidot, C | 1 |
| Horstman, LL | 1 |
| Ahn, YS | 1 |
| van den Boogaard, FE | 1 |
| Schouten, M | 1 |
| de Stoppelaar, SF | 1 |
| Roelofs, JJ | 1 |
| Brands, X | 1 |
| Schultz, MJ | 1 |
| van't Veer, C | 1 |
| van der Poll, T | 1 |
| Stefanini, L | 1 |
| Paul, DS | 1 |
| Robledo, RF | 1 |
| Chan, ER | 1 |
| Getz, TM | 1 |
| Campbell, RA | 1 |
| Kechele, DO | 1 |
| Casari, C | 1 |
| Piatt, R | 1 |
| Caron, KM | 1 |
| Mackman, N | 1 |
| Weyrich, AS | 1 |
| Parrott, MC | 1 |
| Boulaftali, Y | 1 |
| Adams, MD | 1 |
| Peters, LL | 1 |
| Bergmeier, W | 1 |
| Sharma, A | 1 |
| Ferguson, C | 1 |
| Bainey, KR | 1 |
| Hechler, B | 1 |
| Maître, B | 1 |
| Magnenat, S | 1 |
| Heim, V | 1 |
| El Mdawar, MB | 1 |
| Gachet, C | 2 |
| de la Salle, H | 1 |
| Lauritzen, B | 1 |
| Tranholm, M | 1 |
| Ezban, M | 1 |
| Wang, TY | 1 |
| Ou, FS | 1 |
| Roe, MT | 1 |
| Harrington, RA | 1 |
| Ohman, EM | 1 |
| Gibler, WB | 1 |
| Peterson, ED | 1 |
| Wojciechowska, M | 1 |
| Grzywanowska-Łaniewska, I | 1 |
| Załeska-Zydlewska, I | 1 |
| Dłuzniewski, M | 1 |
| Tacke, J | 1 |
| Lindhoff-Last, E | 1 |
| Lokhandwala, JO | 1 |
| Best, PJ | 1 |
| Butterfield, JH | 1 |
| Skelding, KA | 1 |
| Scott, T | 1 |
| Blankenship, JC | 1 |
| Buckley, JW | 1 |
| Berger, PB | 1 |
| Yusuf, SW | 1 |
| Iliescu, C | 1 |
| Bathina, JD | 1 |
| Daher, IN | 1 |
| Durand, JB | 1 |
| Pevzner, DV | 1 |
| Staroverov, II | 1 |
| Samko, AN | 1 |
| Frolova, NS | 1 |
| Mazurov, AV | 1 |
| Ruda, MY | 1 |
| Tebaldi, M | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Yang, EH | 1 |
| Perez, E | 1 |
| Zhiroff, KA | 1 |
| Burstein, S | 1 |
| Yamashita, KM | 1 |
| Nogueira, TO | 1 |
| Senise, LV | 1 |
| Cirillo, MC | 1 |
| Gonçalves, LR | 1 |
| Sano-Martins, IS | 1 |
| Giorgi, R | 1 |
| Santoro, ML | 1 |
| van Velzen, JF | 1 |
| Laros-van Gorkom, BA | 1 |
| Pop, GA | 1 |
| van Heerde, WL | 1 |
| Liu, A | 1 |
| Saman, H | 1 |
| Pusalkar, P | 1 |
| Jerkić, H | 1 |
| Letilović, T | 1 |
| Skorić, KN | 1 |
| Skorić, B | 1 |
| Mestrović, IP | 1 |
| Pocanić, D | 1 |
| Kozmar, D | 1 |
| Kranjcević, S | 1 |
| Hu, Y | 1 |
| Yuan, M | 1 |
| Lu, X | 1 |
| Griffiths, C | 1 |
| Fisher, M | 1 |
| Symeonidis, A | 1 |
| Kouraklis-Symeonidis, A | 1 |
| Seimeni, U | 1 |
| Galani, A | 1 |
| Giannakoulas, N | 1 |
| Fragopanagou, E | 1 |
| Tiniakou, M | 1 |
| Matsouka, P | 1 |
| Zoumbos, N | 1 |
| Collart, F | 1 |
| Derouck, D | 1 |
| Kerbaul, F | 1 |
| Feier, H | 1 |
| Mesana, TG | 1 |
| Helft, G | 1 |
| Elalamy, I | 1 |
| Laudy, C | 1 |
| Tran, D | 1 |
| Beygui, F | 1 |
| Le Feuvre, C | 1 |
| Ounissi, F | 1 |
| Monnet de Lorbeau, B | 1 |
| Khellaf, C | 1 |
| Metzger, JP | 1 |
| Makino, T | 1 |
| Wakushima, H | 1 |
| Okamoto, T | 1 |
| Okukubo, Y | 1 |
| Deguchi, Y | 1 |
| Kano, Y | 1 |
| Igaki, N | 1 |
| Matsuda, T | 1 |
| Yatani, H | 1 |
| Kawaguchi, T | 1 |
| Kida, A | 1 |
| Yanase, K | 1 |
| Moriguchi, R | 1 |
| Sakai, M | 1 |
| Tamada, F | 1 |
| Goto, T | 1 |
| Selleng, K | 1 |
| Selleng, S | 1 |
| Raschke, R | 1 |
| Schmidt, CO | 1 |
| Rosenblood, GS | 1 |
| Greinacher, A | 1 |
| Warkentin, TE | 1 |
| Eryonucu, B | 1 |
| Tuncer, M | 1 |
| Erkoc, R | 1 |
| Suciu, O | 1 |
| Le Hello, C | 1 |
| Maïza, D | 1 |
| Gautier, P | 1 |
| Tiaden, JD | 1 |
| Wenzel, E | 1 |
| Berthold, HK | 1 |
| Müller-Oerlinghausen, B | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Lesurtel, M | 1 |
| Graf, R | 1 |
| Aleil, B | 1 |
| Walther, DJ | 1 |
| Tian, Y | 1 |
| Jochum, W | 1 |
| Bader, M | 1 |
| Clavien, PA | 1 |
| Krolick, MA | 1 |
| Grube, E | 1 |
| Laborde, JC | 1 |
| Gerckens, U | 1 |
| Felderhoff, T | 1 |
| Sauren, B | 1 |
| Buellesfeld, L | 1 |
| Mueller, R | 1 |
| Menichelli, M | 1 |
| Schmidt, T | 1 |
| Zickmann, B | 1 |
| Iversen, S | 1 |
| Stone, GW | 1 |
| Panak, E | 1 |
| Blanchard, J | 1 |
| Roe, RL | 1 |
| Butler, KD | 1 |
| White, AM | 1 |
| Claas, FH | 1 |
| de Fraiture, WH | 1 |
| Meyboom, RH | 1 |
| Renner, C | 1 |
| Guilmet, D | 1 |
| Curtet, JM | 1 |
| Carlson, JA | 1 |
| Maesner, JE | 1 |
| Virdee, M | 1 |
| Collinson, J | 1 |
| Stables, RH | 1 |
| Friedman, ND | 1 |
| Sitlington, R | 1 |
| Lodge, RS | 1 |
| Love, BB | 1 |
| Biller, J | 1 |
| Gent, M | 2 |
| Gawaz, M | 1 |
| Ruf, A | 1 |
| Neumann, FJ | 1 |
| Pogátsa-Murray, G | 1 |
| Dickfeld, T | 1 |
| Zohlnhöfer, D | 1 |
| Schömig, A | 1 |
| Szto, GY | 1 |
| Linnemeier, TJ | 1 |
| Ball, MW | 1 |
| Koornstra, JJ | 1 |
| Loualidi, A | 1 |
| de Vries, CJ | 1 |
| Velin, P | 1 |
| Dupont, D | 1 |
| Golkar, A | 1 |
| Valla, JS | 1 |
| Haas, S | 1 |
| Walenga, JM | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Dunlop, H | 1 |
| Siu, K | 1 |
| Dillon, WC | 1 |
| Eckert, GJ | 1 |
| Dillon, JC | 1 |
| Ritchie, ME | 1 |
| Patnode, NM | 1 |
| Gandhi, PJ | 1 |
| Elmi, F | 1 |
| Peacock, T | 1 |
| Schiavone, J | 1 |
| Taniuchi, M | 1 |
| Kurz, HI | 1 |
| Lasala, JM | 1 |
| Makoni, SN | 1 |
| Reed, MD | 1 |
| Bell, D | 1 |
| Moimeaux, V | 1 |
| Taieb, A | 1 |
| Legrain, V | 1 |
| Meraud, JP | 1 |
| Jimenez, M | 1 |
| Choussat, A | 1 |
| Maleville, J | 1 |
| Teillac-Hamel, D | 1 |
| Andry, P | 1 |
| Bodemer, C | 1 |
| Hubert, P | 1 |
| Sebag, G | 1 |
| Brunelle, F | 1 |
| Nihoul-Fékété, C | 1 |
| de Prost, Y | 1 |
| Herbert, JM | 1 |
| Bernat, A | 2 |
| Maffrand, JP | 2 |
| Takishita, S | 1 |
| Kawazoe, N | 1 |
| Yoshida, T | 1 |
| Fukiyama, K | 1 |
| Tsujinaka, T | 1 |
| Itoh, T | 1 |
| Uemura, Y | 1 |
| Sakon, M | 1 |
| Kambayashi, J | 1 |
| Mori, T | 1 |
| Vallee, E | 1 |
| Gordon, JL | 1 |
| Damas, J | 1 |
| Grek, V | 1 |
| Remacle-Volon, G | 1 |
| Mannucci, PM | 1 |
| Vicente, V | 1 |
| Vianello, L | 1 |
| Cattaneo, M | 1 |
| Alberca, I | 1 |
| Coccato, MP | 1 |
| Faioni, E | 1 |
| Mari, D | 1 |
| Hatsuoka, M | 1 |
| Seiki, M | 1 |
| Sasaki, K | 1 |
| Kashii, A | 1 |
| Pina-Cabral, JM | 1 |
| Ribeiro-da-Silva, A | 1 |
| Almeida-Dias, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vacuum vs Manual Drainage During Unilateral Thoracentesis: A Randomized Trial[NCT03496987] | 100 participants (Actual) | Interventional | 2015-12-01 | Completed | |||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| CoreValve® System Australia/New Zealand Clinical Study[NCT01015612] | 634 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis[NCT00837954] | Phase 4 | 32 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who had procedure termination prior to complete evacuation of the pleural contents (usually as a result of refractory pain or another symptom that the patient perceived). (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Manual Drainage | 1 |
| Vacuum Bottle Drainage | 8 |
"Difference in pain between pre-procedural pain and during drainage pain as measured as the difference between a pre-procedural NPSS pain score (range from 0 (no pain) to 10 (maximum pain)). This was asked again during drainage and the difference between the two was recorded. The values ranged from -10 to 10 (with a more negative number representing a decrease in pain and a more positive number representing an increase in pain)~The scale used is called The Numeric Pain Rating Scale. With ratings from 0-10. Zero is the least amount of pain experienced while 10 is the worst pain possible." (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Pre-post NPRS Pain Scale Score (Mean) |
|---|---|
| Manual Drainage | 0.53 |
| Vacuum Bottle Drainage | 1.43 |
Actual time of drainage in seconds for each patient. (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | seconds (Mean) |
|---|---|
| Manual Drainage | 498.5 |
| Vacuum Bottle Drainage | 318.6 |
Volume of effusion drained (in mL) (NCT03496987)
Timeframe: <20 minutes
| Intervention | milliters (Mean) |
|---|---|
| Manual Drainage | 1023 |
| Vacuum Bottle Drainage | 1143 |
Clinical etiology of effusion (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Malignant | Paramalignant | Heart Failure | Hepatic Hydrothorax | Post-Cardiothoracic Procedure | Parapneumonic | Unknown | |
| Manual Drainage | 13 | 7 | 7 | 3 | 13 | 3 | 3 |
| Vacuum Bottle Drainage | 8 | 2 | 8 | 5 | 17 | 2 | 8 |
Any complications that occur as a direct result of the procedure. We tracked patients for 7 days after the procedure to capture any complications (which is typical clinical practice) (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pneumothorax | Hemothorax | Clinically Significant Pulmonary Edema | |
| Manual Drainage | 0 | 0 | 0 |
| Vacuum Bottle Drainage | 3 | 1 | 1 |
is defined per Valve Academic Research Consortium-1 consensus document (VARC-1), including Cardiovascular and non-cardiovascular mortality. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.038 |
Defined as all death resulting from a cardiac cause or complications of a cardiac procedure and / or death of an unknown cause; this category includes valve-related deaths and non-valve-related cardiac deaths (e.g. congestive heart failure, acute myocardial infarction, documented fatal arrhythmias). (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.035 |
Defined as a composite of all cause death, myocardial infarction(MI) (Q-wave & non-Q-wave), stroke, and re-intervention (defined as any emergent cardiac surgery or percutaneous re-intervention catheter procedure that repairs, otherwise alters or adjusts or replaces a previously implanted valve) (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.099 |
Included Q-wave and non-Q-wave. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.021 |
"Vascular access, delivery and deployment of the device, and retrieval of the delivery system~Correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function)~Intended performance of the prosthetic valve (aortic valve area > 1.2 cm2 (by echocardiography using the continuity equation) and mean aortic valve gradient < 20 mmHg, without moderate or severe prosthetic valve aortic regurgitation)~Only one valve implanted~No occurrence of in-hospital MACCE" (NCT01015612)
Timeframe: 24-48 hours after the procedure or before the discharge
| Intervention | % of participants with device success (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 52.6 |
Any emergent surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.019 |
Is a neurological deficit lasting more than 24 hours, or lasting 24 hours or less with a brain imaging study showing infarction. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.043 |
8 reviews available for ticlopidine and Thrombocytopenia
| Article | Year |
|---|---|
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2015 |
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2010 |
Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.
Topics: Age Distribution; Aged; Aged, 80 and over; Agranulocytosis; Anemia, Aplastic; Anti-Bacterial Agents; | 2002 |
Adverse haematological effects of ticlopidine. Prevention, recognition and management.
Topics: Anemia, Aplastic; Cerebrovascular Disorders; Female; Humans; Male; Neutropenia; Platelet Aggregation | 1998 |
Drug-induced thrombocytopenia in the coronary care unit.
Topics: Anticoagulants; Coronary Care Units; Diagnosis, Differential; Fibrinolytic Agents; Heparin; Humans; | 2000 |
Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Catheterization; Clopidogrel | 2001 |
Clinical pharmacology of bivalirudin.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as | 2002 |
8 trials available for ticlopidine and Thrombocytopenia
| Article | Year |
|---|---|
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Bioprosthe | 2006 |
Evaluation of the antithrombotic efficacy of ticlopidine in man.
Topics: Anticoagulants; Clinical Trials as Topic; Extracorporeal Circulation; Female; Fibrinolytic Agents; H | 1984 |
[Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Cardiac Surgical Procedures; Extracorporeal Circulation; | 1980 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time.
Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Clinical Trials as Topic; Deamino Arginine Vasopres | 1986 |
52 other studies available for ticlopidine and Thrombocytopenia
| Article | Year |
|---|---|
Chronic Thrombocytopenia and Percutaneous Coronary Intervention: The Virtue of Prudence.
Topics: Humans; Percutaneous Coronary Intervention; Thrombocytopenia; Ticlopidine; Treatment Outcome; Virtue | 2018 |
Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; China; Clopidogrel; Cross-Sectional Studies; Defib | 2013 |
The safety of thoracentesis in patients with uncorrected bleeding risk.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Clopidogrel; Cohort Studies; D | 2013 |
Red cell-derived microparticles (RMP) as haemostatic agent.
Topics: Adenosine Diphosphate; Animals; Bleeding Time; Blood Coagulation Disorders; Busulfan; Cell Separatio | 2013 |
Thrombocytopenia impairs host defense during murine Streptococcus pneumoniae pneumonia.
Topics: Animals; Antithrombin III; Clopidogrel; Cytokines; Disease Models, Animal; Mice; Peptide Hydrolases; | 2015 |
RASA3 is a critical inhibitor of RAP1-dependent platelet activation.
Topics: Animals; Cellular Senescence; Clopidogrel; GTPase-Activating Proteins; Guanine Nucleotide Exchange F | 2015 |
Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Diphtheri | 2016 |
rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
Topics: Animals; Clopidogrel; Factor VII; Factor VIIa; Hemorrhage; Hemostasis; Platelet Count; Rats; Recombi | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
[From gastroenteritis complicated by acute renal failure to... the Moschcowitz syndrome].
Topics: Acute Kidney Injury; Aged; Diagnosis, Differential; Gastroenteritis; Humans; Male; Plasmapheresis; P | 2009 |
Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel.
Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Female; Humans; Male; Neutropenia; | 2009 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2010 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Corona | 2011 |
Involvement of circulating platelets on the hyperalgesic response evoked by carrageenan and Bothrops jararaca snake venom.
Topics: Animals; Aspirin; Blood Platelets; Bothrops; Busulfan; Carrageenan; Clopidogrel; Crotalid Venoms; Cy | 2011 |
Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers.
Topics: Aspirin; Blood Platelets; Clopidogrel; Flow Cytometry; Humans; Platelet Activation; Platelet Aggrega | 2012 |
Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum.
Topics: Adult; Aspirin; Clopidogrel; Eisenmenger Complex; Epistaxis; Female; Humans; Platelet Aggregation In | 2011 |
[Antiaggregation therapy after percutaneous coronary intervention in a patient with thrombocytopenia: case report].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Male; Platelet Aggregation; Plat | 2011 |
Thrombocytopenia induced by both aspirin and clopidogrel in the same patient.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Platelet Aggregation Inhibitors; Thrombocytopenia; Ticlo | 2013 |
Abciximab-induced thrombocytopenia.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Diagnosis, Differential; Hemolytic-U | 2002 |
Regression of intracardiac heparin-induced thrombosis after aortic root surgery.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug | 2003 |
[Clopidogrel and thrombopenia. A case report].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Humans; Male; | 2003 |
Pharmacokinetic and pharmacological interactions between ticlopidine hydrochloride and Kangen-Karyu - Chinese traditional herbal medicine.
Topics: Administration, Oral; Animals; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions | 2003 |
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi | 2003 |
Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Fe | 2005 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedul | 2004 |
[Does antiaggregant therapy have a place in type II heparin-induced thrombocytopenia?].
Topics: Aged; Clopidogrel; Fatal Outcome; Female; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation | 2005 |
Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Aspirin; Association; | 2005 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Platelet-derived serotonin mediates liver regeneration.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Blood Platelets; Busulfan; Cell Proliferation; Clopidogr | 2006 |
Successful percutaneous coronary intervention using bivalirudin in a patient with chronic lymphocytic leukemia and thrombocytopenia.
Topics: Aged; Cardiac Catheterization; Clopidogrel; Hirudins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2006 |
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen | 1980 |
[Thrombocytopenia due to antibodies induced by ticlopidine].
Topics: Aged; Antibody Formation; Anticoagulants; Arteriosclerosis; Blood Platelets; Humans; Platelet Count; | 1984 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine.
Topics: Aged; Aged, 80 and over; Fatal Outcome; Humans; Male; Neutropenia; Thrombocytopenia; Ticlopidine | 1994 |
Ticlopidine and renal function.
Topics: Acute Kidney Injury; Creatinine; Drug Eruptions; Humans; Kidney; Male; Middle Aged; Platelet Aggrega | 1996 |
Thrombocytopenia and hepatitis complicating ticlopidine therapy.
Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Male; Platelet Aggregation Inhibitors; Thrombo | 1997 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.
Topics: Aged; Coronary Disease; Coronary Thrombosis; Fatal Outcome; Female; Humans; Male; Middle Aged; Neutr | 1999 |
Ticlopidine-induced thrombocytopenia.
Topics: Coronary Disease; Female; Follow-Up Studies; Humans; Middle Aged; Platelet Aggregation Inhibitors; P | 1999 |
-Neonatal Kasabach-Merritt syndrome healed by complete surgical excision of the angioma-.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Back; Glucocorticoids; Hemangioma; Humans; Infant, | 1998 |
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
Topics: Adenosine Triphosphate; Anticoagulants; Benzylamines; Blood Platelets; Dose-Response Relationship, D | 1999 |
Serious hematologic reactions associated with ticlopidine--update.
Topics: Adverse Drug Reaction Reporting Systems; Hemorrhage; Humans; Leukopenia; Patient Education as Topic; | 1999 |
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet | 2000 |
Isolated profound thrombocytopenia associated with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Follow-Up Studies; Humans; | 2000 |
Aspirin-ticlopidin in Kasabach-Merritt syndrome.
Topics: Aspirin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Thr | 1992 |
[Kasabach-Merritt syndrome in children].
Topics: Aspirin; Child, Preschool; Disseminated Intravascular Coagulation; Embolization, Therapeutic; Hemang | 1992 |
Importance of platelets in experimental venous thrombosis in the rat.
Topics: Animals; Blood Platelets; Clopidogrel; Disease Models, Animal; Heparin; Hirudins; Leukopenia; Male; | 1992 |
Ticlopidine and thrombocytopenia.
Topics: Aged; Humans; Male; Thrombocytopenia; Ticlopidine | 1990 |
Clinical application of a new in vitro bleeding time device on surgical patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Bleeding Time; Epoprostenol; Hemorrhage; Hemostasis; H | 1988 |
The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat.
Topics: Adenosine Diphosphate; Animals; Blood Platelets; Blood Transfusion; Clopidogrel; Male; Platelet Coun | 1988 |
Inhibition of the thrombocytopenic effect of exogenous and endogenous thrombin by PCR 4099 (d,1)methyl 2-(2-chlorophenyl)-2(4,5,6, 7-tetrahydrothieno (3,2-c)pyridin-5-yl) acetate.hydrochloride.monohydrate.
Topics: Animals; Carrageenan; Clopidogrel; Ellagic Acid; Female; Hypotension; Male; Platelet Aggregation Inh | 1987 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techni | 1986 |
Platelet sequestration during hypothermia in dogs treated with sulphinpyrazone and ticlopidine--reversibility accelerated after intra-abdominal rewarming.
Topics: Animals; Blood Platelets; Dogs; Hemodynamics; Hot Temperature; Hypothermia; Liver; Platelet Aggregat | 1985 |